Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ: STIM )

4.360 +0.460 (+11.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 128 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 73 companies reached new 52-week lows. 
Via Benzinga
Neuronetics's Return On Capital Employed Overview
Via Benzinga
Preview: Neuronetics's Earnings
Via Benzinga
Neuronetics Announces Expanded TMS Therapy Access Through Aetna® Health Plans
Policy Updates Impact Nationwide Commercial Plans for 16.8 Million Covered Lives 
From Neuronetics
Via GlobeNewswire
Neuronetics' NeuroStar Gets Regulatory Clearance In South Korea
Neuronetics, Inc. (NASDAQ: STIM) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved multiple features of NeuroStar TMS (transcranial magnetic stimulation) for  
Via Benzinga
NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment 
From Neuronetics
Via GlobeNewswire
Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS
Via Benzinga
NeuroStar Achieves Milestone Regulatory Clearance in South Korea
First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ Technologies 
From Neuronetics
Via GlobeNewswire
Neuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced Therapy
The Company expands technology for patients with obsessive-compulsive disorder 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
Lower Medication Requirement Helps Depression Patients Obtain Treatment Sooner 
From Neuronetics
Via GlobeNewswire
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy 
From Neuronetics
Via GlobeNewswire
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
The Company is recognized for its commitment to employees’ well-being 
From Neuronetics
Via GlobeNewswire
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products 
From Neuronetics
Via GlobeNewswire
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes 
From Neuronetics
Via GlobeNewswire
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
Campaign features patients’ experiences to support others with depression 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Expanded TMS Access through United HealthCare
UHC Medicare Advantage plans in NGS states expand access via NPPs 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience 
From Neuronetics
Via GlobeNewswire
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeing 
From Neuronetics
Via GlobeNewswire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients 
From Neuronetics
Via GlobeNewswire
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For Providers 
From Neuronetics
Via GlobeNewswire
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS 
From Neuronetics
Via GlobeNewswire
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety 
From Neuronetics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.